Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics (Nasdaq: VRDN) announced the approval of inducement grants for 10 new employees. The grants consist of non-qualified stock options to purchase 391,500 shares of common stock, approved by the company's Compensation Committee on December 2, 2024. The options were granted outside the company's Amended and Restated 2016 Equity Incentive Plan but follow its terms and conditions.
The exercise price equals the closing price of Viridian's stock on the grant date. The options will vest over four years, with 25% vesting after one year and the remaining shares vesting in 36 monthly installments, subject to continued employment.
Viridian Therapeutics (Nasdaq: VRDN) ha annunciato l'approvazione di concessioni incentivanti per 10 nuovi dipendenti. Le concessioni consistono in opzioni su azioni non qualificate per l'acquisto di 391.500 azioni ordinarie, approvate dal Comitato per la Remunerazione dell'azienda il 2 dicembre 2024. Le opzioni sono state concesse al di fuori del Piano di Incentivazione Azionaria modificato e ripristinato del 2016, ma seguono i suoi termini e condizioni.
Il prezzo di esercizio è pari al prezzo di chiusura delle azioni di Viridian alla data di concessione. Le opzioni si matureranno in quattro anni, con il 25% che si matura dopo un anno e le rimanenti azioni che si maturano in 36 rate mensili, soggette a un impiego continuativo.
Viridian Therapeutics (Nasdaq: VRDN) anunció la aprobación de concesiones de incentivo para 10 nuevos empleados. Las concesiones consisten en opciones de acciones no calificadas para comprar 391,500 acciones ordinarias, aprobadas por el Comité de Compensación de la empresa el 2 de diciembre de 2024. Las opciones se otorgaron fuera del Plan de Incentivo de Capital enmendado y restablecido de 2016, pero siguen sus términos y condiciones.
El precio de ejercicio es igual al precio de cierre de las acciones de Viridian en la fecha de concesión. Las opciones se consolidarán durante cuatro años, con el 25% consolidándose después de un año y las acciones restantes consolidándose en 36 cuotas mensuales, sujeto a empleo continuo.
Viridian Therapeutics (Nasdaq: VRDN)은 10명의 새로운 직원에 대한 유인 보상 승인 사실을 발표했습니다. 보상은 391,500주를 구매할 수 있는 비자격 주식 옵션으로 구성되어 있으며, 2024년 12월 2일 회사 보상 위원회에서 승인되었습니다. 옵션은 회사의 수정 및 재작성된 2016년 자본 인센티브 계획 외부에서 부여되지만, 그 조건을 따릅니다.
행사가격은 보상 날짜의 Viridian 주식 종가와 같습니다. 이 옵션은 4년에 걸쳐 정산됩니다, 1년 후 25%가 정산되고 나머지 주식은 36개월의 월별 분할로 정산되며, 지속적인 고용을 조건으로 합니다.
Viridian Therapeutics (Nasdaq: VRDN) a annoncé l'approbation de subventions d'incitation pour 10 nouveaux employés. Les subventions consistent en des options d'actions non qualifiées pour l'achat de 391 500 actions ordinaires, approuvées par le Comité de Rémunération de l'entreprise le 2 décembre 2024. Les options ont été attribuées en dehors du Plan d'Incentives en Actions modifié et rétabli de 2016, mais suivent ses termes et conditions.
Le prix d'exercice est égal au prix de clôture de l'action Viridian à la date de la subvention. Les options s'acquittent sur une période de quatre ans, avec 25 % s'acquittant après un an et les actions restantes s'acquittant en 36 versements mensuels, sous réserve d'un emploi continu.
Viridian Therapeutics (Nasdaq: VRDN) gab die Genehmigung von Anreizvergaben für 10 neue Mitarbeiter bekannt. Die Vergaben bestehen aus nicht qualifizierten Aktienoptionen zum Kauf von 391.500 Stammaktien, die am 2. Dezember 2024 vom Vergütungsausschuss des Unternehmens genehmigt wurden. Die Optionen wurden außerhalb des geänderten und neu gefassten Aktienvergütungsplans von 2016 gewährt, folgen jedoch dessen Bedingungen.
Der Ausübungspreis entspricht dem Schlusskurs der Viridian-Aktie am Tag der Vergabe. Die Optionen reif werden über einen Zeitraum von vier Jahren, wobei 25% nach einem Jahr reif werden und die verbleibenden Aktien in 36 monatlichen Teilbeträgen reif werden, vorbehaltlich einer kontinuierlichen Beschäftigung.
- Stock-based compensation aligns employee interests with shareholders
- Expansion of workforce with 10 new hires indicates company growth
- Potential shareholder dilution from 391,500 new stock options
The Inducement Grants have an exercise price per share that is equal to the closing price of Viridian’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with
About Viridian Therapeutics
Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED.
In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Viridian is based in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241204813695/en/
Anabel Chan, 617-458-8725
Vice President, Investor Relations & Communications
IR@viridiantherapeutics.com
Louisa Stone, 617-272-4604
Manager, Investor Relations
IR@viridiantherapeutics.com
Source: Viridian Therapeutics, Inc.
FAQ
How many shares were included in Viridian Therapeutics (VRDN) December 2024 inducement grants?
What is the vesting schedule for Viridian Therapeutics (VRDN) December 2024 inducement grants?
How many new employees received Viridian Therapeutics (VRDN) inducement grants in December 2024?
